Fig. 1: Preparation and characterization of nanomedicines. | Nature Communications

Fig. 1: Preparation and characterization of nanomedicines.

From: MMP-2-triggered, mitochondria-targeted PROTAC-PDT therapy of breast cancer and brain metastases inhibition

Fig. 1

a Schematic illustration of the composition of dBET6@CFMPD and its therapeutic effect on primary breast cancer and brain metastases. a Created with BioRender.com released under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International license. The DLS results and TEM images of b dBET6@CPD, c dBET6@CFPD, and d dBET6@CFMPD (scale bar = 200 nm). The molecular mass changes of CFPD (e) and CFMPD (f) after incubation with MMP-2 for 4 and 24 h were detected by MALDI-TOF-MS analyses. MALDI-TOF-MS spectra of e, f are included in Supplementary Figs. 10 and 11. g The TEM images of dBET6@CFMPD after incubation with MMP-2 (scale bar = 2 μm). The TEM images and enlarged images of cells treated with CFPD (h) and CFMPD (i). Red arrows and blue arrows indicate spherical nanoparticles and nanofibers, respectively (scale bar = 500 nm). Source data are provided as a Source Data file.

Back to article page